On Breakingviews – Biotech undergoes the ultimate trial by epidemic, says mak_robyn
A worker is seen at the manufacturing workshop of vaccine maker Wuhan Institute of Biological Products in Wuhan, Hubei province, China May 26, 2010. Picture taken May 26, 2010. REUTERS/Stringer ATTENTION EDITORS - THIS IMAGE WAS PROVIDED BY A THIRD PARTY. CHINA OUT.
Epidemics are bad business for pharmaceutical companies; stopping them is risky and expensive. After factoring in regulatory approvals, it can take years to put a drug on the market - often after an outbreak has burned out. Merck’s Ebola vaccine, for example, was only approved by the U.S. authorities in December, more than five years after the disease peaked in West Africa. And even if treatment is developed in time, politicians tend to lean on producers to keep prices low.
Progress on the coronavirus sounds encouraging. A handful claim they can have a vaccine ready for clinical testing in as little as 90 days; it took roughly 20 months to start testing during the 2003 SARS epidemic.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
China to stagger back to work as virus deaths surpass SARS tollChina raised the death toll from the coronavirus epidemic to 811 on Sunday, pass...
Read more »
China to stagger back to work as coronavirus deaths surpass SARSChina raised the death toll from the coronavirus epidemic to 811 on Sunday, pass...
Read more »
China to stagger back to work as coronavirus deaths surpass SARSChina raised the death toll from the coronavirus epidemic to 811 on Sunday, pass...
Read more »
Breakingviews - iPhones will display China's back-to-work powerOn Breakingviews – iPhones will display China’s back-to-work power, writes mak_robyn:
Read more »
New Zealand says can manage coronavirus impact on economyA coronavirus epidemic will have an 'inevitable' impact on New Zealand...
Read more »